Ondine Biomedical Inc
LSE:OBI
Net Margin
Ondine Biomedical Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
CA |
O
|
Ondine Biomedical Inc
LSE:OBI
|
40.4m GBP |
-874%
|
|
US |
![]() |
Abbott Laboratories
NYSE:ABT
|
219.3B USD |
32%
|
|
US |
![]() |
Intuitive Surgical Inc
NASDAQ:ISRG
|
181.3B USD |
28%
|
|
US |
![]() |
Boston Scientific Corp
NYSE:BSX
|
150.8B USD |
11%
|
|
US |
![]() |
Stryker Corp
NYSE:SYK
|
140.3B USD |
13%
|
|
IE |
![]() |
Medtronic PLC
NYSE:MDT
|
113.2B USD |
13%
|
|
US |
![]() |
Becton Dickinson and Co
NYSE:BDX
|
66.1B USD |
8%
|
|
DE |
![]() |
Siemens Healthineers AG
XETRA:SHL
|
56.6B EUR |
9%
|
|
US |
![]() |
Edwards Lifesciences Corp
NYSE:EW
|
41.8B USD |
77%
|
|
CN |
![]() |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
293.4B CNY |
33%
|
|
US |
![]() |
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
37B USD |
10%
|
Ondine Biomedical Inc
Glance View
Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Ondine Biomedical Inc's most recent financial statements, the company has Net Margin of -873.6%.